Carboplatin and paclitaxel treatment is effective in advanced anal cancer

Richard Kim, Jennifer Byer, William J. Fulp, Amit Mahipal, William Dinwoodie, David Shibata

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: The development of distant metastases of squamous cell carcinoma of the anal canal (SCCA) is rare but has a poor prognosis. A combination of carboplatin and paclitaxel is commonly used for treating squamous cell cancer in different organs, but its efficacy in advanced SCCA is unclear. The objective of this study is to determine the tolerability and outcome of patients with advanced SCCA on carboplatin plus paclitaxel treatment at the Moffitt Cancer Center. Methods: Retrospective analysis was conducted by looking at records from the Moffitt Cancer Center Tumor Registry from January 2007 to January 2012. Eligible patients had to have a diagnosis of SCCA and have received carboplatin plus paclitaxel every 3 weeks as part of the treatment plan. Results: Eighteen patients fulfilled the criteria; 14 were initially diagnosed with early-stage disease and received concurrent chemoradiation, but then relapsed. Median age was 56 years. Upon diagnosis of metastatic disease, 12 patients received carboplatin plus paclitaxel as a first-line treatment. Five patients had received prior systemic chemotherapy regimens and 1 had received prior local regional therapy. The response rate was high at 53% including 3 patients who achieved a complete response. Median overall survival was 12.19 months. Conclusions: Carboplatin and paclitaxel treatment shows encouraging activity in advanced SCCA.

Original languageEnglish (US)
Pages (from-to)125-132
Number of pages8
JournalOncology (Switzerland)
Volume87
Issue number2
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Anus Neoplasms
Carboplatin
Paclitaxel
Anal Canal
Squamous Cell Carcinoma
Therapeutics
Squamous Cell Neoplasms
Neoplasms
Registries
Neoplasm Metastasis
Drug Therapy
Survival

Keywords

  • Anal cancer
  • Carboplatin
  • Paclitaxel

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Carboplatin and paclitaxel treatment is effective in advanced anal cancer. / Kim, Richard; Byer, Jennifer; Fulp, William J.; Mahipal, Amit; Dinwoodie, William; Shibata, David.

In: Oncology (Switzerland), Vol. 87, No. 2, 01.01.2014, p. 125-132.

Research output: Contribution to journalArticle

Kim, R, Byer, J, Fulp, WJ, Mahipal, A, Dinwoodie, W & Shibata, D 2014, 'Carboplatin and paclitaxel treatment is effective in advanced anal cancer', Oncology (Switzerland), vol. 87, no. 2, pp. 125-132. https://doi.org/10.1159/000361051
Kim, Richard ; Byer, Jennifer ; Fulp, William J. ; Mahipal, Amit ; Dinwoodie, William ; Shibata, David. / Carboplatin and paclitaxel treatment is effective in advanced anal cancer. In: Oncology (Switzerland). 2014 ; Vol. 87, No. 2. pp. 125-132.
@article{b5a55b07644648c3bab339749198bb4c,
title = "Carboplatin and paclitaxel treatment is effective in advanced anal cancer",
abstract = "Background: The development of distant metastases of squamous cell carcinoma of the anal canal (SCCA) is rare but has a poor prognosis. A combination of carboplatin and paclitaxel is commonly used for treating squamous cell cancer in different organs, but its efficacy in advanced SCCA is unclear. The objective of this study is to determine the tolerability and outcome of patients with advanced SCCA on carboplatin plus paclitaxel treatment at the Moffitt Cancer Center. Methods: Retrospective analysis was conducted by looking at records from the Moffitt Cancer Center Tumor Registry from January 2007 to January 2012. Eligible patients had to have a diagnosis of SCCA and have received carboplatin plus paclitaxel every 3 weeks as part of the treatment plan. Results: Eighteen patients fulfilled the criteria; 14 were initially diagnosed with early-stage disease and received concurrent chemoradiation, but then relapsed. Median age was 56 years. Upon diagnosis of metastatic disease, 12 patients received carboplatin plus paclitaxel as a first-line treatment. Five patients had received prior systemic chemotherapy regimens and 1 had received prior local regional therapy. The response rate was high at 53{\%} including 3 patients who achieved a complete response. Median overall survival was 12.19 months. Conclusions: Carboplatin and paclitaxel treatment shows encouraging activity in advanced SCCA.",
keywords = "Anal cancer, Carboplatin, Paclitaxel",
author = "Richard Kim and Jennifer Byer and Fulp, {William J.} and Amit Mahipal and William Dinwoodie and David Shibata",
year = "2014",
month = "1",
day = "1",
doi = "10.1159/000361051",
language = "English (US)",
volume = "87",
pages = "125--132",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "2",

}

TY - JOUR

T1 - Carboplatin and paclitaxel treatment is effective in advanced anal cancer

AU - Kim, Richard

AU - Byer, Jennifer

AU - Fulp, William J.

AU - Mahipal, Amit

AU - Dinwoodie, William

AU - Shibata, David

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: The development of distant metastases of squamous cell carcinoma of the anal canal (SCCA) is rare but has a poor prognosis. A combination of carboplatin and paclitaxel is commonly used for treating squamous cell cancer in different organs, but its efficacy in advanced SCCA is unclear. The objective of this study is to determine the tolerability and outcome of patients with advanced SCCA on carboplatin plus paclitaxel treatment at the Moffitt Cancer Center. Methods: Retrospective analysis was conducted by looking at records from the Moffitt Cancer Center Tumor Registry from January 2007 to January 2012. Eligible patients had to have a diagnosis of SCCA and have received carboplatin plus paclitaxel every 3 weeks as part of the treatment plan. Results: Eighteen patients fulfilled the criteria; 14 were initially diagnosed with early-stage disease and received concurrent chemoradiation, but then relapsed. Median age was 56 years. Upon diagnosis of metastatic disease, 12 patients received carboplatin plus paclitaxel as a first-line treatment. Five patients had received prior systemic chemotherapy regimens and 1 had received prior local regional therapy. The response rate was high at 53% including 3 patients who achieved a complete response. Median overall survival was 12.19 months. Conclusions: Carboplatin and paclitaxel treatment shows encouraging activity in advanced SCCA.

AB - Background: The development of distant metastases of squamous cell carcinoma of the anal canal (SCCA) is rare but has a poor prognosis. A combination of carboplatin and paclitaxel is commonly used for treating squamous cell cancer in different organs, but its efficacy in advanced SCCA is unclear. The objective of this study is to determine the tolerability and outcome of patients with advanced SCCA on carboplatin plus paclitaxel treatment at the Moffitt Cancer Center. Methods: Retrospective analysis was conducted by looking at records from the Moffitt Cancer Center Tumor Registry from January 2007 to January 2012. Eligible patients had to have a diagnosis of SCCA and have received carboplatin plus paclitaxel every 3 weeks as part of the treatment plan. Results: Eighteen patients fulfilled the criteria; 14 were initially diagnosed with early-stage disease and received concurrent chemoradiation, but then relapsed. Median age was 56 years. Upon diagnosis of metastatic disease, 12 patients received carboplatin plus paclitaxel as a first-line treatment. Five patients had received prior systemic chemotherapy regimens and 1 had received prior local regional therapy. The response rate was high at 53% including 3 patients who achieved a complete response. Median overall survival was 12.19 months. Conclusions: Carboplatin and paclitaxel treatment shows encouraging activity in advanced SCCA.

KW - Anal cancer

KW - Carboplatin

KW - Paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=84903864979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903864979&partnerID=8YFLogxK

U2 - 10.1159/000361051

DO - 10.1159/000361051

M3 - Article

C2 - 25012155

AN - SCOPUS:84903864979

VL - 87

SP - 125

EP - 132

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 2

ER -